Background: Preeclampsia is a major obstetric problem and a significant source of maternal and neonatal morbidity and mortality. Preeclampsia is associated with increased risks of placental abruption, acute renal failure, cerebrovascular and cardiovascular complications, disseminated intravascular coagulation, and maternal death. Consequently, early diagnosis of preeclampsia and close observation are imperative. In these cases of preeclampsia, combination of Doppler flowmetry and circulating angiogenic factors levels are recorded. Stepan et al examined endoglin, a cell-surface co-receptor for transforming growth factor in patients with Doppler flow patterns of preeclampsia at 19-24 weeks. Soluble endoglin levels were elevated ...
Objectives: To examine the performance of screening for preeclampsia (PE) by a combination of mat...
BACKGROUND: Despite intensive research, the etiopathogenesis of preeclampsia (PE) remains uncertain....
BACKGROUND: Alterations in circulating soluble fms-like tyrosine kinase 1 (sFlt1), an antiangiogenic...
Background: Preeclampsia is a multisystem disorder of unknown etiology that affects 4–5% of all preg...
Background: The purpose of this study was to compare plasma soluble endoglin (sEng) levels with stan...
BACKGROUND: The purpose of this study was to compare plasma soluble endoglin (sEng) levels with stan...
Abstract Objective: To analyze th e differences of maternal serum soluble endoglin level in pr ee...
Objectives: To determine and compare the serum soluble Endoglin (sEng) levels among pregnant women w...
Objective: Abnormal trophoblastic invasion and impaired placentation have a crucial role in the etio...
Background: Poor placentation at early gestational age is an important predisposing condition for th...
Objective: To evaluate the use of a new marker in the prediction of pre-eclampsia few months before ...
OBJECTIVES: To evaluate soluble endoglin (sEng) and the soluble fms-like tyrosine kinase 1 (sFlt1) t...
OBJECTIVES: To evaluate soluble endoglin (sEng) and the soluble fms-like tyrosine kinase 1 (sFlt1) t...
Serum levels of endoglin were measured in pre-eclamptic women in their third trimester and in women ...
Objective: In preeclampsia, there will be an increase in SFlt-1 and in and decrease in PlGF levels. ...
Objectives: To examine the performance of screening for preeclampsia (PE) by a combination of mat...
BACKGROUND: Despite intensive research, the etiopathogenesis of preeclampsia (PE) remains uncertain....
BACKGROUND: Alterations in circulating soluble fms-like tyrosine kinase 1 (sFlt1), an antiangiogenic...
Background: Preeclampsia is a multisystem disorder of unknown etiology that affects 4–5% of all preg...
Background: The purpose of this study was to compare plasma soluble endoglin (sEng) levels with stan...
BACKGROUND: The purpose of this study was to compare plasma soluble endoglin (sEng) levels with stan...
Abstract Objective: To analyze th e differences of maternal serum soluble endoglin level in pr ee...
Objectives: To determine and compare the serum soluble Endoglin (sEng) levels among pregnant women w...
Objective: Abnormal trophoblastic invasion and impaired placentation have a crucial role in the etio...
Background: Poor placentation at early gestational age is an important predisposing condition for th...
Objective: To evaluate the use of a new marker in the prediction of pre-eclampsia few months before ...
OBJECTIVES: To evaluate soluble endoglin (sEng) and the soluble fms-like tyrosine kinase 1 (sFlt1) t...
OBJECTIVES: To evaluate soluble endoglin (sEng) and the soluble fms-like tyrosine kinase 1 (sFlt1) t...
Serum levels of endoglin were measured in pre-eclamptic women in their third trimester and in women ...
Objective: In preeclampsia, there will be an increase in SFlt-1 and in and decrease in PlGF levels. ...
Objectives: To examine the performance of screening for preeclampsia (PE) by a combination of mat...
BACKGROUND: Despite intensive research, the etiopathogenesis of preeclampsia (PE) remains uncertain....
BACKGROUND: Alterations in circulating soluble fms-like tyrosine kinase 1 (sFlt1), an antiangiogenic...